Lung cancer is the second most frequently diagnosed cancer, and the leading cause of cancer deaths in the United Kingdom. Two thirds of patients present with advanced disease, which contributes significantly to the high mortality rate associated with this disease. Radiation therapy (RT) is used frequently in the treatment of lung cancer, however the delivery of tumouricidal doses is often limited by the risk of radiation induced lung toxicity (RILT). RILT occurs in an acute phase as pneumonitis followed by a later phase of fibrosis. Because the RILT symptoms are often similar to those of pulmonary infection or disease progression, diagnosis can be difficult. Approaches to improving the outcome of RT for lung cancer include: 1. Detection of ...
Purpose: In lung cancer radiation therapy, the dose constraints are determined mostly by healthy lun...
PURPOSE: Our hypothesis was that pretreatment inflammation in the lung makes pulmonary tissue more s...
Lung cancer is the largest contributor to cancer-related mortality worldwide. Only 20% of stage III ...
SummaryA new method to assess radiation-induced lung toxicity (RILT) using CT-scans was developed. I...
This study demonstrated a method that can characterize the development of FLASH and conventional rad...
Lung cancer is the leading cause of cancer related death. Radiation therapy is a prominent treatment...
A new method to assess radiation-induced lung toxicity (RILT) using CT-scans was developed. It is mo...
Radiation therapy is an important therapeutic modality for thoracic malignancies. However, radiation...
Radiation pneurnonitis (RP) and radiation fibrosis (RF) are two dose-limiting toxicities of radiothe...
Background and purpose: Preclinical models are much needed to assess the effect of novel radiosensit...
Background: Radiotherapy is widely used in the treatment of lung cancer, with both curative and pall...
The results presented in this thesis explored the associations of a quantitative lung damage endpoin...
Background Radiation-induced pulmonary fibrosis (RIPF) is a frequent outcome of thoracic radiation...
Radiation-induced lung injury (RILI), including acute radiation pneumonitis and chronic radiation-in...
Abstract Background. Radiation-induced lung damage (RILD) is an important problem. Although physical...
Purpose: In lung cancer radiation therapy, the dose constraints are determined mostly by healthy lun...
PURPOSE: Our hypothesis was that pretreatment inflammation in the lung makes pulmonary tissue more s...
Lung cancer is the largest contributor to cancer-related mortality worldwide. Only 20% of stage III ...
SummaryA new method to assess radiation-induced lung toxicity (RILT) using CT-scans was developed. I...
This study demonstrated a method that can characterize the development of FLASH and conventional rad...
Lung cancer is the leading cause of cancer related death. Radiation therapy is a prominent treatment...
A new method to assess radiation-induced lung toxicity (RILT) using CT-scans was developed. It is mo...
Radiation therapy is an important therapeutic modality for thoracic malignancies. However, radiation...
Radiation pneurnonitis (RP) and radiation fibrosis (RF) are two dose-limiting toxicities of radiothe...
Background and purpose: Preclinical models are much needed to assess the effect of novel radiosensit...
Background: Radiotherapy is widely used in the treatment of lung cancer, with both curative and pall...
The results presented in this thesis explored the associations of a quantitative lung damage endpoin...
Background Radiation-induced pulmonary fibrosis (RIPF) is a frequent outcome of thoracic radiation...
Radiation-induced lung injury (RILI), including acute radiation pneumonitis and chronic radiation-in...
Abstract Background. Radiation-induced lung damage (RILD) is an important problem. Although physical...
Purpose: In lung cancer radiation therapy, the dose constraints are determined mostly by healthy lun...
PURPOSE: Our hypothesis was that pretreatment inflammation in the lung makes pulmonary tissue more s...
Lung cancer is the largest contributor to cancer-related mortality worldwide. Only 20% of stage III ...